Sheikhbahaei Sara, Marcus Charles, Hafezi-Nejad Nima, Taghipour Mehdi, Subramaniam Rathan M
Russell H Morgan Department of Radiology and Radiological Sciences, Johns Hopkins School of Medicine, JHOC 3230, 601 North Caroline Street, Baltimore, MD 21287, USA.
Russell H Morgan Department of Radiology and Radiological Sciences, Johns Hopkins School of Medicine, JHOC 3230, 601 North Caroline Street, Baltimore, MD 21287, USA; Department of Oncology, Johns Hopkins School of Medicine, 401 North Broadway, Baltimore, MD 21231, USA; Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, 624 North Broadway, Baltimore, MD 21205, USA.
PET Clin. 2015 Jul;10(3):375-93. doi: 10.1016/j.cpet.2015.03.003. Epub 2015 Apr 16.
Fluorodeoxyglucose (FDG)-PET/computed tomography (CT) has been increasingly used in bone and soft tissue sarcomas and provides advantages in the initial tumor staging, tumor grading, therapy assessment, and recurrence detection. FDG-PET/CT metabolic parameters are reliable predictors of survival in sarcomas and could be implemented in risk stratification models along with other prognostic factors in these patients.
氟代脱氧葡萄糖（FDG）-正电子发射断层显像（PET）/计算机断层扫描（CT）已越来越多地应用于骨与软组织肉瘤，在肿瘤初始分期、分级、治疗评估及复发检测方面具有优势。FDG-PET/CT代谢参数是肉瘤生存的可靠预测指标，可与这些患者的其他预后因素一起用于风险分层模型。
